FDA to Expand Its Authority Over Stem-Cell Treatment Facilities – Wall Street Journal (subscription)
Wall Street Journal (subscription) |
FDA to Expand Its Authority Over Stem–Cell Treatment Facilities
Wall Street Journal (subscription) The Food and Drug Administration is stepping up oversight of fledgling medical treatments that aim to harness the potential of stem cells—as well as some businesses that the agency said were selling unapproved and possibly harmful treatments. The FDA … |
Reuters |
FDA steps up scrutiny of stem cell therapies
Reuters A small number of “unscrupulous actors” have seized on the promise of regenerative medicine and stem cell therapies to mislead patients based on unproven, and in some cases, dangerously dubious products, the FDA said on Monday. (bit.ly/2iB4Xls). |
|
Biotech stocks surge on Gilead’s Kite Pharma acquisition
MarketWatch The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T–cell therapy, or CAR-T, which uses a patient’s immune T–cells and re-engineers them to better fight cancer. Juno, Bluebird and … |
Genetic Engineering & Biotechnology News |
When Two Immunotherapy Rights Make a Wrong
Genetic Engineering & Biotechnology News Recent advances in immunotherapy have given many cancer patients stricken with tumors intractable to current therapies hope for meaningful remission times. While researchers continue to try and understand the intricacies of the immune system’s response … |
UCalgary News |
Researchers discover new immunotherapy combination effective at …
UCalgary News “We’ve been looking at these cancer drugs the wrong way — as tumour-targeting drugs — instead of what we now feel is their most important biological role: as … |